Making a difference with your help.
Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Sponsor: Boehringer Ingelheim Indication: CKD GFR: 20-90 DETAILS >
Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Sponsor: AstraZeneca Indication: CKD & HTN GFR: 30-89 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Sponsor: Bayer Indication: CKD & HTN GFR: ≥20 and ≤75 DETAILS >
Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Read More »
Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity GFR: 21-75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Sponsor: Alpine Immune Sciences / Vertex Indication: IgA Nephropathy GFR: ≥30 DETAILS >
Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/- V Sponsor: Novartis Indication: Lupus Nephritis GFR: ≥ 25 DETAILS >
Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study Protocol – Fabry Disease Registry Read More »
Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication: Antineutrophil Cytoplasmic
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »
Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS GFR: > 30 Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >